• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom plans Apple Watch CGM launch

June 17, 2019 By Danielle Kirsh

Dexcom updated logoDexcom Inc. (NSDQ:DXCM) is launching upgrades for its G6 diabetes system and plans to launch its direct-to-Apple Watch version over the next year.

The Apple and Dexcom collaboration would allow diabetes patients to track glucose through the Apple Watch, a consumer wearable, according to CNBC.

“It’s coming,” Dexcom CEO Kevin Sayer told the network. “And this tool is great for people with diabetes.”

Dexcom’s G6 continuous glucose monitoring system is designed for people with diabetes ages two and up. The device includes a transmitter and a sensor with an auto-applicator. A touchscreen receiver is also available. The G6 eliminates the need for finger sticks and the glucose readings are sent to any Bluetooth-enabled smart device.

“It takes a CGM and makes it much smaller,” Sayer said. “It really will be a device, we think, for the ages and a platform forever. It’s going to be wonderful.”

Dexcom partnered with UnitedHealth in November 2017 to test the CGM and is partnering with Walgreens and CVS in the future.

“We want to be where our patients want to be met, not in our plant or not someplace else,” Sayer said. “[We want to] get the product to the patient where they can use it.”

Dexcom won Health Canada approval for its G6 device earlier this year and plans to commercially launch later in 2019. With more than 8 million people in the U.S. and Europe on insulin therapy, the company wants to launch the G6 system in the Medicare market.

“I assure you there is plenty of room for us to grow over the long term,” Sayer said.

Filed Under: Diabetes Tagged With: DexCom Inc.

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS